-transparent.png){kind=logo}
Serum carbonic anhydrase III (CA-III) levels were determined by means of an enzyme immunoassay method and compared with serum creatine kinase (CK) and muscle-specific enolase (MSE) levels in 143 patients with four types of progressive muscular dystrophy (PMD), namely, Duchenne muscular dystrophy (DMD), limb-girdle dystrophy, facioscapulohumeral dystrophy and congenital dystrophy. Serum CA-III levels were raised in the majority of patients, especially in those with DMD. In DMD patients, the gradual decline in the CA-III level was observed with age. High correlations were found between CA-III, CK and MSE levels. The frequency of cases with elevated CA-III levels was the same as or greater than that of elevated CK or MSE levels in four types of PMD. These results suggest that serum CA-III may be a useful marker of muscle disease.
K Mokuno, and
S Riku, and
Y Matsuoka, and
I Sobue, and
K Kato
September 1983,
Clinica chimica acta; international journal of clinical chemistry,
K Mokuno, and
S Riku, and
Y Matsuoka, and
I Sobue, and
K Kato
September 1980,
Lancet (London, England),
K Mokuno, and
S Riku, and
Y Matsuoka, and
I Sobue, and
K Kato
December 1961,
Helvetica paediatrica acta,
K Mokuno, and
S Riku, and
Y Matsuoka, and
I Sobue, and
K Kato
January 1991,
Clinical chemistry,
K Mokuno, and
S Riku, and
Y Matsuoka, and
I Sobue, and
K Kato
January 1985,
American journal of medical genetics,
K Mokuno, and
S Riku, and
Y Matsuoka, and
I Sobue, and
K Kato
January 1982,
Lancet (London, England),
K Mokuno, and
S Riku, and
Y Matsuoka, and
I Sobue, and
K Kato
June 1985,
American journal of medical genetics,
K Mokuno, and
S Riku, and
Y Matsuoka, and
I Sobue, and
K Kato
November 1957,
Munchener medizinische Wochenschrift (1950),
K Mokuno, and
S Riku, and
Y Matsuoka, and
I Sobue, and
K Kato
January 1980,
Advances in experimental medicine and biology,
K Mokuno, and
S Riku, and
Y Matsuoka, and
I Sobue, and
K Kato
March 1966,
Nihon rinsho. Japanese journal of clinical medicine,
